


**PRODUCT: GDC0994**

**ALTERNATE NAMES:** GDC 0994; GDC-0994; Ravoxertinib; RG7842; RG-7842; RG 7842; 1-[(1S)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-4-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]pyridin-2-one

**CATALOG#:** B1629-5, -25

**AMOUNT:** 5 mg, 25 mg

**STRUCTURE:**



**MOLECULAR FORMULA:** C<sub>21</sub>H<sub>18</sub>ClFN<sub>6</sub>O<sub>2</sub>

**MOLECULAR WEIGHT:** 440.86

**CAS NUMBER:** 1453848-26-4

**APPEARANCE:** Solid powder

**SOLUBILITY:** DMSO

**PURITY:** >98%

**STORAGE:** Dry, dark and at 4°C for short term (days to weeks) or at -20°C for long term. Protect from air and light.

**DESCRIPTION:** GDC-0994 is highly selective inhibitor of extracellular signal-regulated kinase (ERK), ERK1 and ERK2, with biochemical potency of 1.1 nM and 0.3 nM, respectively.

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**RELATED PRODUCTS:**

- Alsterpaullone (Cat. No. 1897-1,5)
- AZD-6244 (Cat. No. 2234-5, 25)
- BIX01289 (Cat. No. 2670-1,5)
- Butyrolactone I (Cat. No. 1690-200)
- Doramapimod (Cat. No. 1954-5, 25)
- Flavopiridol (Cat. No. 2090-1, 5)
- 10Z-Hymenialdisine (Cat. No. 2212-250, 1000)
- Kenpaullone (Cat. No. 1904-1)
- MEK-162 (Cat. No. 2254-5, 25)
- PD1834352 (CI-1040) (Cat. No. 1585-1,5,25)
- EZSolution™ PD184352 (Cat. No. 1871-1)
- PD325901 (Cat. No. 1643-2, 5, 25)
- PD98059 (Cat. No. 1666-5)
- EZSolution™ PD98059 (Cat. No. 1783-5)
- RO-3306 (Cat. No. 2039-1,5)
- Roscovitine (Cat. No. 1950-1,5)
- SB 203580 (Cat. No. 1712-1, 5)
- EZSolution™ SB203580 (1786-1)
- SB202190 (Cat. No. 2493-5, 25)
- Sorafenib (Cat. No. 1594-25, 100)
- TAK733 (Cat. No. 2460-5, 25)
- TG003 (Cat. No. 1905-5, 25)
- 7, 3', 4'-Trihydroxyisoflavone (1886-25, 100)
- U0126 (Cat. No. 1668-5)
- VX-702 (Cat. No. 1598-1,5)
- VX-745 (Cat. No. 2812-5, 25)

**USAGE:** *FOR RESEARCH USE ONLY! Not to be used in humans*